<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637154</url>
  </required_header>
  <id_info>
    <org_study_id>MoHa</org_study_id>
    <nct_id>NCT02637154</nct_id>
  </id_info>
  <brief_title>Motivational Interview in Adolescents With Poorly Controlled Type 1 Diabetes</brief_title>
  <official_title>The Effect of Motivational Interview and Intensive Education on HbA1C Values and Glucose Variability in Adolescents With Poorly Controlled Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effect of motivational interviewing and intensive education on
      HbA1c values and glucose variability in poorly controlled adolescent T1D patients.

      In the present study motivational interviewing (MI) will be integrated to clinicians' daily
      practice, as a part of normal clinical visit. In this randomized, controlled trial hypothesis
      is, that applying motivational interviewing during regular clinical visits results in better
      acceptance and subsequently enhanced metabolic control in adolescents with poorly controlled
      type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Type 1 diabetes (T1D) patients with optimal glycemic control suffer markedly less
      from long term diabetic complications than those with poor control. Increased glycohemoglobin
      (HbA1C) levels predict the complication risk. The development of diabetic complications seems
      to accelerate during puberty, and poor metabolic control during adolescence or young
      adulthood markedly increases the incidence of micro- or macrovascular complications during
      subsequent years. On the other hand, intensive treatment during adolescence has been reported
      to reduce the risk of microvascular complications, even if the control later on becomes
      poorer. This implicates that interventions targeting at improved glycemic control during
      adolescence probably have sustained beneficial effects on the overall morbidity in patients
      T1D.

      The glycemic control of Finnish adolescents with T1D is poor. Insulin resistance and impaired
      metabolic control are common problems. Treatment of the disease during puberty can be
      complicated and particularly treatment adherence often declines in youth. Inexpensive and
      easily adoptable methods for clinicians are needed to overcome treatment problems faced with
      adolescent patients.

      At present, there are no generally recommended approaches for clinicians to apply in order to
      motivate adolescents with poor glycemic control towards better treatment adherence. To this
      end, motivational interviewing (MI) has been used to an increasing degree in health care
      professionals in the treatment of variety of disorders and behavioral problems, such as
      alcohol and drug problems, gambling, and cardiovascular diseases. Motivational interviewing
      is a counseling approach designed to facilitate intrinsic motivation in the patient to change
      behavior. Significant body of evidence supports the view that MI improves commitment to care
      when added to other treatment. However, only a few studies have evaluated MI in the treatment
      of adolescent diabetes patients, with outcomes ranging from substantial benefit to neutral.
      MI is a promising approach for the treatment adolescent type 1 diabetics but there is a clear
      demand for methodologically solid studies.

      Aims The aim of the present study is to investigate the effect of motivational interviewing
      and intensive education on HbA1c values and glucose variability in poorly controlled
      adolescent T1D patients. Secondarily, it will be investigated whether improved glycemic
      control is associated with improvements in vascular parameters, metabolic markers, markers of
      bone health and health related quality of life.

      Hypothesis In the present study motivational interviewing (MI) will be integrated to
      clinicians' daily practice, as a part of normal clinical visit. In this randomized,
      controlled trial hypothesis is, that applying motivational interviewing during regular
      clinical visits results in better acceptance and subsequently enhanced metabolic control in
      adolescents with poorly controlled type 1 diabetes.

      Study protocol All physicians participating in the study are trained to use standardized
      educational (SE) material. In addition half of the physicians are randomized to motivational
      interview (MI) group. They are trained by professor Martti Tuomisto's group to use MI in a
      one day workshop with refresher practical rehearsal course prior to study start. To secure
      that MI is sufficiently applied, the physician/patient discussions will be monitored by the
      Tuomisto group. All researchers randomized to the MI group will receive continuous feedback
      from the Tuomisto group on their performance (i.e. level of applying MI) and if needed
      re-trained for MI.

      Patients with Hba1c &gt; 75 mmol/mol are identified from hospital records, and are considered
      eligible for the current study. The patients willing to participate are randomized either to
      MI plus SE or SE group.

      Study Protocol Every visit includes a physical examination (including evaluation of the stage
      of puberty and testis volume at the start and at 12 months), measurement of height, weight,
      growth velocity, body mass index (BMI), blood pressure and waist circumference, usage of SE
      material, and in the MI group usage of MI during the patient visit. The intervention in the
      MI group consists of a MI type of introduction at the beginning of each patient visit, and
      applying MI principles and procedures on each educational item discussed during the patient
      visit. Adherence to MI intervention protocols will be checked using recorded samples of
      therapy interactions. HbA1c levels are also measured in every visit.

      Six days blinded continuous glucose monitoring will be performed at baseline and during the
      follow-up (0, 6 and 12 months).

      Fasting venous blood samples are obtained at baseline and at 12 months. Investigators will
      evaluate health related quality of life (QoL) in study participants at baseline, and at
      completion of the study.

      Dual- energy x-absorptiometry (DXA) is performed at baseline and at 12 months. Vascular
      assessments will be performed at baseline and at study completion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1C values (mmol/mol)</measure>
    <time_frame>12 months</time_frame>
    <description>HbA1c levels (mmol/mol) are measured in every visit (AfinionTM).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glycaemic variability</measure>
    <time_frame>12 months</time_frame>
    <description>Six days blinded continuous glucose monitoring (CGM) (iPro, Medtronic) will be performed at baseline and during the follow-up. Blinded CGM curves (0 and 12mo) will be analyzed to study effect on glycemic variability. Standard deviation (SD) of blood glucose values and mean amplitude of glycemic excursions (MAGE) will be used as parameters to define glycemic variability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of changes in markers of vascular health (IMT)</measure>
    <time_frame>12 months</time_frame>
    <description>The association between glycemic control and vascular wall morphology is assessed by imaging of the carotid, femoral, brachial and radial artery intima media thickness (IMT as millimeters - mm:s) with ultrasound. Results will be compared to previously established measurements from healthy children. Vascular assessment will be performed at baseline and at study completion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of changes in markers of vascular health (PWV)</measure>
    <time_frame>12 months</time_frame>
    <description>The association between glycemic control and central and peripheral arterial thickness is assessed with pulse wave velocity (PWV - as meters / second - m/s) using applanation tonometry. Results will be compared to previously established measurements from healthy children. Vascular assessments will be performed at baseline and at study completion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of changes in bone mineral density (BMD)</measure>
    <time_frame>12 months</time_frame>
    <description>Dual- energy x-absorptiometry (DXA) is performed at baseline and at 12 months for analyses of BMD (total body less head, lumbar spine) and body composition, using the Hologic Discovery device (indicated as SD of Z-score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of changes in quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Health related quality of life (QoL) in study participants will be evaluated at baseline, and at completion of the study with the KINDL-R questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of changes in markers of inflammation (IL-6 - pg/ml)</measure>
    <time_frame>12 months</time_frame>
    <description>Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of serum inflammatory marker serum IL-6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of changes in markers of inflammation (high-sensitive-c-reactive-protein CRP - mg/l).</measure>
    <time_frame>12 months</time_frame>
    <description>Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of serum inflammatory marker hs-CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of changes in insulin-like-growth-factor IGF-I levels</measure>
    <time_frame>12 months</time_frame>
    <description>Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of serum insulin-like-growth-factor IGF-I (ng/ml) levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of changes in markers of bone turnover (serum aminoterminal propeptide of type I collagen (PINP - ng/ml)).</measure>
    <time_frame>12 months</time_frame>
    <description>Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of markers of bone turnover (PINP - ng/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of changes in vitamin D status (25-hydroxy-D) ng/ml</measure>
    <time_frame>12 months</time_frame>
    <description>Fasting venous blood samples are obtained at baseline and at 12 months for analysis of changes in vitamin D status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of changes in marker of bone turnover: osteocalcin (ng/ml)</measure>
    <time_frame>12 months</time_frame>
    <description>Fasting venous blood samples are obtained at baseline and at 12 months for analysis of changes in bone turnover marker osteocalcin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of changes in marker of bone turnover: aminoterminal telopeptide of type I collagen (INTP - ng/ml)</measure>
    <time_frame>12 months</time_frame>
    <description>Fasting venous blood samples are obtained at baseline and at 12 months for analysis of changes in bone turnover marker INTP.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Motivational Interviewing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>With 30 patients Motivational Interviewing method will be used during each visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Education</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>With 30 patients Standard Education material will be used during each visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Interviewing</intervention_name>
    <description>Motivational Interviewing method</description>
    <arm_group_label>Motivational Interviewing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Education</intervention_name>
    <description>Standard Education material will be used</description>
    <arm_group_label>Standard Education</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the diagnosis of type 1 diabetes with at least 2 years duration and HbA1c &gt; 75
             mmol/mol on two consecutive visits, age 12-15.9 years and pubertal (Tanner) stage 2 or
             more at inclusion

        Exclusion Criteria:

          -  celiac disease with poor control; diagnosis of psychiatric disease; and other chronic
             disease requiring per oral glucocorticoid treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mari Pulkkinen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Specialist in Pediatric Endocrinology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mari Pulkkinen, MD PhD</last_name>
    <phone>+358504284956</phone>
    <email>mari.pulkkinen@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matti Hero, MD PhD</last_name>
    <phone>+358504286412</phone>
    <email>matti.hero@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Pediatric Diabetes Unit Espoo</name>
      <address>
        <city>Espoo</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mari Pulkkinen, MD PhD</last_name>
      <phone>+358504284956</phone>
      <email>mari.pulkkinen@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Pediatric Endocrinology Unit</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matti Hero, PhD</last_name>
      <phone>+358504286412</phone>
      <email>matti.hero@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Anna-Kaisa Tuomaala, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital, Pediatric Endocrinology Unit</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kari Kaunisto, MD PhD</last_name>
      <email>kari.kaunisto@oulu.fi</email>
    </contact>
    <investigator>
      <last_name>Marja Ojaniemi, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>PÃ¤ivi Tossavainen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009 Jul 27;169(14):1307-16. doi: 10.1001/archinternmed.2009.193.</citation>
    <PMID>19636033</PMID>
  </reference>
  <reference>
    <citation>Bryden KS, Dunger DB, Mayou RA, Peveler RC, Neil HA. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes Care. 2003 Apr;26(4):1052-7.</citation>
    <PMID>12663572</PMID>
  </reference>
  <reference>
    <citation>White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001 Dec;139(6):804-12.</citation>
    <PMID>11743505</PMID>
  </reference>
  <reference>
    <citation>Channon S, Smith VJ, Gregory JW. A pilot study of motivational interviewing in adolescents with diabetes. Arch Dis Child. 2003 Aug;88(8):680-3.</citation>
    <PMID>12876161</PMID>
  </reference>
  <reference>
    <citation>Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005 Apr;55(513):305-12. Review.</citation>
    <PMID>15826439</PMID>
  </reference>
  <reference>
    <citation>Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970 Sep;19(9):644-55.</citation>
    <PMID>5469118</PMID>
  </reference>
  <reference>
    <citation>Valerio G, del Puente A, Esposito-del Puente A, Buono P, Mozzillo E, Franzese A. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res. 2002;58(6):266-72.</citation>
    <PMID>12446989</PMID>
  </reference>
  <reference>
    <citation>Sarkola T, Redington A, Keeley F, Bradley T, Jaeggi E. Transcutaneous very-high-resolution ultrasound to quantify arterial wall layers of muscular and elastic arteries: validation of a method. Atherosclerosis. 2010 Oct;212(2):516-23. doi: 10.1016/j.atherosclerosis.2010.06.043. Epub 2010 Jul 7.</citation>
    <PMID>20673898</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Mari Pulkkinen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Adolescent</keyword>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Metabolic control</keyword>
  <keyword>Motivational interviewing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

